We previously demonstrated that N348I in HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance. However, both of these inhibitors are currently infrequently used in developed countries, and the impact of N348I on newer reverse transcriptase inhibitors, such as tenofovir and etravirine, is unknown. In this study, we demonstrate that N348I alone confers no resistance to tenofovir and low-level resistance to etravirine. However, N348I significantly decreases tenofovir susceptibility when combined with thymidine analogue mutations and etravirine susceptibility when combined with Y181C.
We previously demonstrated that N348I in HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance. However, both of these inhibitors are currently infrequently used in developed countries, and the impact of N348I on newer reverse transcriptase inhibitors, such as tenofovir and etravirine, is unknown. In this study, we demonstrate that N348I alone confers no resistance to tenofovir and low-level resistance to etravirine. However, N348I significantly decreases tenofovir susceptibility when combined with thymidine analogue mutations and etravirine susceptibility when combined with Y181C.
We recently identified the N348I mutation in the connection domain of the HIV-1 reverse transcriptase that confers resistance to both zidovudine (AZT) and nevirapine [1] . N348I is highly prevalent in reverse transcriptase inhibitor (RTI)-experienced patients [1] [2] [3] [4] [5] , occurs early in therapy usually prior to the appearance of recognized thymidine analogue mutations (TAMs) [1] and is associated with an increase in viremia [1] . In our study, N348I was selected by antiretroviral treatments (ARTs) that included AZT or the combination of AZT and nevirapine [1] . N348I has also been reported to confer resistance to didanosine and delavirdine, and its emergence in a Japanese cohort was primarily associated with AZTor didanosine-containing therapies, or both [2] .
The use of AZT, didanosine and nevirapine in ARTs in the developed world has been largely replaced with more potent and less toxic RTIs [6] . For example, the International AIDS Society-USA panel recommends either tenofovir/emtricitabine (Truvada) or abacavir/ lamivudine in combination with efavirenz or ritonavirboosted protease inhibitor for initial combination therapy [6] . Truvada is also used in the treatment of antiretroviralexperienced patients, as is the new nonnucleoside reverse transcriptase inhibitor (NNRTI), etravirine [6] . The genotypic determinants of tenofovir and etravirine resistance have been established. Decreased susceptibility to tenofovir in vitro and in vivo is associated with the K65R mutation or the presence of three or more TAMs (e.g. M41L, L210Wand T215Y) [7] [8] [9] [10] . Decreased etravirine susceptibility requires at least three NNRTI-resistant mutations [11] [12] [13] [14] . Surprisingly, etravirine activity is not compromised by the K103N mutation [11] . To date, it has not been established whether N348I can reduce susceptibility to tenofovir or etravirine and compromise drug activity in treatment-experienced patients. Accordingly, in this study, we determined whether N348I alone, or in combination with TAMs or Y181C, decreased susceptibility to tenofovir or etravirine.
N348I was introduced by site-directed mutagenesis into the background of wild-type, K103N, Y181C, M41L/ L210Y and M41L/L210W/T215Y expressing reverse transcriptase genes of the pNL4.3 (NL) or HXB-2 (HX) infectious molecular clones [15, 16] . HIV was recovered by transfection of 293T cells, and drug susceptibility assays were performed in the TZM-bl indicator cell line, as described previously [1] with the exception that HIV replication was determined by measuring luciferase activity using the Steady-Glo Luciferase Assay System according to manufacturer's instructions (Promega, Madison, Wisconsin, USA). Statistically significant differences in the 50% effective dose (EC 50 ) were determined using the Wilcoxon rank sum test [17] .
Our data (Table 1) demonstrate that N348I (NL/348) alone conferred a 1.6-fold decrease (P ¼ 0.019, n ¼ 4) in etravirine susceptibility as compared with the corresponding wild-type strain. By comparison, Y181C conferred 2.2-fold resistance to etravirine (P ¼ 0.02, n ¼ 4), whereas K103N did not confer a significant change in etravirine susceptibility as compared with wildtype. When combined with K103N, no decrease in etravirine susceptibility was observed as compared with K103N alone, whereas a small decrease in etravirine susceptibility was seen as compared with wild-type (P ¼ 0.019, n ¼ 5) (Table 1) . By contrast, when N348I was combined with Y181C, etravirine susceptibility was decreased 6.4-fold (P ¼ 0.02, n ¼ 4) relative to wild-type virus and 2.9-fold (P ¼ 0.03, n ¼ 4) relative to Y181C HIV-1 (NL/181) ( Table 1) . Consistent with this finding, the Y181C/N348I double mutation also significantly decreased etravirine susceptibility at the enzyme level (data not shown). Taken together, these data demonstrate that N348I confers a small decrease in susceptibility to etravirine and significantly potentiates etravirine resistance in the context of Y181C but not K103N.
As reported previously [18] , HIV-1-containing N348I conferred no significant increase in tenofovir EC 50 as compared with the corresponding wild-type strain (Table 1) . However, when combined with M41L and T215Y (NL/2AZT), N348I decreased tenofovir susceptibility by 1.7-fold (P ¼ 0.014, n ¼ 4) as compared with wild-type. By contrast, the NL/2AZT strain was susceptible to tenofovir ( Table 1) . N348I also increased tenofovir resistance when combined with M41L, L210W and T215Y (HX/3AZT) by six-fold as compared with wild-type (P ¼ 0.009, n ¼ 5) and three-fold as compared with the HX/3AZT strain (P ¼ 0.008, n ¼ 4). In this regard, A371V and Q509L in the connection and RNase H domains, respectively [19] , and mutations located at residues that form part of the RNase H primer grip [20, 21] potentiate resistance to tenofovir in cell culturebased assays when combined with TAMs. Taken together, these data demonstrate that N348I decreases tenofovir susceptibility in the presence of TAMs, and notably, this effect is observed with less than three TAMs.
According to the International AIDS Society-USA panel drug-resistant mutations update, the presence of three or more TAMs inclusive of M41L and L210W is expected to give a reduced in-vivo response to tenofovir [22] . Therefore, in current genotyping algorithms, tenofovir could be prescribed in the presence of two TAMs (e.g. M41L and T215Y) and N348I, which may result in reduced in-vivo drug efficacy. Similarly, we have shown that N348I enhances resistance to etravirine in the context of Y181C, a mutation that is associated with reduced virological response in vivo [13, 14] . As the presence of three or more NNRTI mutations V90I, A98G, L100I, K101E/P, V106I, V179D/F, Y181C/I/V and G190A/S results in no response to etravirine treatment [13, 14] , the presence of two of these NNRTI mutations and N348I at baseline may also reduce etravirine efficacy in vivo.
N348I is not a polymorphism. It is found in treatmentexperienced but rarely in treatment-naive individuals infected with HIV-1 clades A, B, AE, AG, C, D, F and G (http://hivdb.stanford.edu/cgi-bin/AgMutPrev.cgi). Furthermore, the prevalence of Y181C and K103N is 11% and 22%, respectively. Accordingly, at least one in 10 HIV-infected patients will have Y181C prior to etravirine exposure, particularly in patients failing first-line ARTs in resource-poor settings due to the continued use of nevirapine [23] . Accordingly, the acquisition of N348I in HIV-1 reverse transcriptase may significantly impact both first and second-line ARTs in resource-poor settings.
Taken together, our in-vitro data warrant studies to determine the clinical significance of the appearance of a preexisting N348I mutation in regimens containing tenofovir or etravirine. The differences between the etravirine or tenofovir EC 50 values for mutant strain divided by the EC 50 for corresponding wild-type strain. Values above 1 indicate resistance. Statistically significant differences compared with wild-type are denoted in bold type. d The differences between the tenofovir EC 50 for NL and NL2AZT þ 348 (P ¼ 0.014, n ¼ 4), and HX compared with HX/3AZT (P ¼ 0.05, n ¼ 4) and HX/3AZT þ 348 (P ¼ 0.009, n ¼ 5) were statistically significant as was HX/3AZT þ 348 compared with HX/3AZT (P ¼ 0.008, n ¼ 4). The difference in the tenofovir EC 50 values for NL/2AZT and HX/348 compared with the corresponding wild-type strain was not statistically significant.
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There are no conflicts of interest. We show that the V75I variant has decreased sensitivity to some nucleoside analogs but an increased sensitivity to zidovudine, results that may guide selection of highly active antiretroviral therapy regimens in patients harboring this variant.
Herpes simplex virus 2 (HSV-2) is a common copathogen in HIV-1 infected individuals, and coinfection is widespread in regions such as sub-Saharan Africa [1] . Each pathogen can enhance severity of symptoms of the other infection [1] [2] [3] [4] . Recent clinical trials with the antiherpetic drug acyclovir or its prodrug valacyclovir have been designed to modulate HIV-1 disease by control of HSV-2 outbreaks in HSV-2/HIV-1 coinfected patients not on highly active antiretroviral therapy (HAART). These trials demonstrated an approximately 0.5 log 10 decrease in HIV-1 plasma levels [5, 6] . It is known that HIV-1 disease progression is strongly correlated with plasma viral load [7] , and thus the modest decrease in HIV-1 plasma levels observed with acyclovir may be beneficial in prolonging time to initiation of HAART or the onset of AIDS. Acyclovir trials in large cohorts of HIV-1 infected participants are currently underway including HSV-2 seronegative patients who may also benefit from acyclovir therapy [8] . Acyclovir has also been studied as a means of prophylaxis against the acquisition of HIV-1 in HSV-2-infected individuals [9, 10] . Although acyclovir did not decrease the risk of acquisition, HIV-1 viral loads in acyclovir-treated patients were lower than those of the control group. Therefore, the benefit of acyclovir treatment in coinfected individuals continues to be explored.
Interestingly, in-vitro data revealed that the clinical observations cited above may be a result of direct inhibition of HIV-1 replication by acyclovir. Biochemical studies have shown that acyclovir triphosphate is a substrate of HIV-1 reverse transcriptase [11, 12] . In addition, the V75I multidrug resistance mutation in HIV-1 reverse transcriptase was selected for in vitro under the selective pressure of acyclovir and pseudotyped virus containing this mutation was less sensitive to acyclovir than wild-type virus [12] . These data provide an alternative hypothesis to the generally accepted theory that the control of HSV-2 infection indirectly decreases HIV-1 replication. Although HIV-1 resistance to acyclovir has yet to be reported in patients, in-vitro data suggest this is a possibility. In the similar case of entecavir, the unexpected discovery of the anti-HIV-1 activity of this hepatitis B drug and selection for the M184V reverse transcriptase mutation in patients [13] has led to modifications of treatment recommendations in coinfected individuals [14] . Similarly, monitoring HIV-1 genotypes in patients taking acyclovir monotherapy may be critical for optimizing future treatment.
Importantly, the WHO recommends a first line regimen of two nucleoside reverse transcriptase inhibitors (NRTIs), and one nonnucleoside reverse transcriptase inhibitor (NNRTI), for resource limited countries including sub-Saharan Africa. Zidovudine or tenofovir are the preferred NRTIs in this regimen in combination with lamivudine or emtricitabine [15] . As the majority of participants in the acyclovir clinical trials were from resource limited countries, a better understanding of treatment and resistance may be helpful in guiding future HAART regimens.
Because V75I is the only HIV-1 mutation associated with acyclovir, we evaluated the sensitivity of the V75I variant to FDA approved NRTIs. To do this, we used a sensitive single round HIV infectivity assay [13, 16, 17] . Wildtype and V75I HIV-1 proviral constructs with green fluorescent protein (GFP) gene in place of HIV envelope were pseudotyped with the chemokine receptor CXCR4 tropic HIV envelope, and the resulting pseudoviruses were used to infect primary activated CD4 þ lymphoblasts isolated from normal donors in the presence of increasing concentrations of the indicated NRTIs. The level of HIV-1 replication was determined by quantifying the number of GFPþ cells 3 days post infection by flow cytometry.
Surprisingly, V75I mutant virus was hypersusceptible to zidovudine compared with wild-type virus (Fig. 1a ). Current biochemical investigations into the mechanism of this hypersusceptibility are underway. However, as illustrated in Fig. 1b , the V75I mutant virus was modestly less sensitive to lamivudine, emtricitabine, and didanosine compared with wild-type virus, slightly less sensitive to abacavir, and there was a relative equal sensitivity to tenofovir and stavudine. Biochemical data suggest that the main mechanism of resistance of V75I reverse transcriptase to acyclovir triphosphate is an increased discrimination against the analog compared with 2'deoxyguanosine 5'-triphosphate (dGTP) [18] . It will be interesting if this is the mechanism as well that explains the resistance to some of the NRTIs. Nevertheless, if the V75I mutation is selected in patients taking acyclovir monotherapy, a first line HAART regimen containing zidovudine may exceed expectations.
One of the most important remaining questions is whether acyclovir monotherapy will continue to be beneficial for HIV-1 infected patients or will selection of resistant virus, possibly the V75I variant, affect treatment options. Most clinical trials so far have administered lower doses of acyclovir or valacyclovir to study participants, whereas selection of the V75I variant in vitro was seen at higher acyclovir concentrations. As illustrated in Fig. 1c , a comparison of fitness of wild-type versus V75I virus in the presence of acyclovir in the single round infectivity assay shows that replication of wild-type virus is favored over mutant at peak plasma concentrations ($20 mmol/l) determined from standard dosing. Thus, the V75I variant may not be selected in patients at this dose. In contrast, a comparison of fitness of wild-type virus with M184V virus in the presence of lamivudine (Fig. 1c) clearly shows that replication of M184V virus is favored at clinical concentrations of drug, consistent with the rapid selection of this mutant in patients [19] [20] [21] . Nonetheless, acyclovir has shown to be a well tolerated drug and, at a higher 2 g/day dose of the prodrug valacyclovir, the steady state plasma concentrations of acyclovir can reach approximately 38 mmol/l [22] . At these concentrations, low level resistant virus, not detectable by clinical genotypes, could exist and potentially be archived affecting future treatment.
In conclusion, the available clinical data demonstrate a benefit to treatment with acyclovir in HSV-2/HIV-1 coinfected patients not on HAART [5, 6] . The V75I mutant virus, selected by acyclovir treatment in vitro, is hypersusceptible to zidovudine, a drug that is currently recommended as the first line NRTI for treatment of HIV-1 in resource limited countries. Continued investigation into the interplay between HSV-2 and HIV-1 as well as the effect of acyclovir with both viruses will facilitate the development of treatment options for HIV-1 infected patients with the continued goal of increasing patient survival and decreasing side effects of drug burden and toxicity. Interferon gamma (IFNg)-based in-vitro assays have suboptimal sensitivity, especially in immunocompromised individuals, which emphasizes the need for alternative markers for tuberculosis (TB) diagnosis. We compared TB antigens-specific IFNg and IFNg-inducible protein-10 levels in culture of whole blood samples from HIV-TB patients. We report that IFNg-inducible protein-10 detects a greater number of HIV-TB cases than IFNg and suggest that IFNg-inducible protein-10 may be a better alternative marker for latent TB infection diagnosis among immunocompromised individuals.
The accelerated progression of tuberculosis (TB) in HIV infection [1, 2] and the higher risk of mortality [3, 4] demands diagnostic tests that detect Mycobacterium tuberculosis infection and disease at an early stage. Recently developed T-cell-based interferon gamma (IFNg) release assays (IGRAs) have shown promise in the diagnosis of latent TB infection (LTBI). These assays are also being evaluated for diagnosis of active disease. Unlike tuberculin skin test (TST), they are least affected by prior Bacillus Calmette-Guerin vaccination and environmental mycobacteria [5] . IGRAs are commercially available in two formats: QuantiFERON-TB Gold in-tube (QFT-IT; Cellestis Inc., Valencia, California, USA) and T-SPOT.TB (Oxford Immunotec, Oxford, UK). Although IGRAs perform better than TST in immunocompromised individuals, they have suboptimal sensitivity in those individuals [6] [7] [8] . Particularly, QFT-IT gives more indeterminate results (3-17%) than T.SPOT.TB due to the paucity of the source of IFNg, namely the CD4 þ T cells [9] .
Recently, IFNg-inducible protein-10 was suggested as a better diagnostic marker for TB infection [10] [11] [12] [13] [14] . A study [10] with very few individuals reported higher sensitivity of IFNg-inducible protein-10 over IGRAs. Nonetheless, the utility of IFNg-inducible protein-10 among HIV-infected individuals has not been evaluated so far. The present study compared the levels of IFNg and IFNg-inducible protein-10 in the culture of whole blood samples from HIV-TB patients.
A total of 50 newly diagnosed, smear-positive HIV-TB patients were recruited for this study. Six sputum samples were collected from each patient. Concentrated sputum samples were used for smear microscopy, and the smearpositive sputum samples were cultured in Lowenstein Jensen (Biomerieux Inc., Marcy I'Etoile, France) and also in liquid MP BacT medium (Biomerieux Inc.). Study participants' age ranged from 18 to 54 (median 38) years, and 72% of them were men. Forty-five individuals were HIV-1 positive and five were dually infected. Blood was drawn for CD3, CD4 and CD8 cell counts, QFT-IT and inducible protein-10 assays.
QFT-IT was carried out as per the manufacturer's instructions (Cellestis Ltd., Carnegie, Victoria, Australia), and the results were interpreted using the software supplied. IFNg-inducible protein-10 levels were measured in the supernatants from QFT-IT tubes using BD Opt-EIA kits (BD Biosciences, San Jose, California, USA). Briefly, capture antibody (mouse antihuman inducible protein-10 mAb) in carbonate-bicarbonate buffer (pH 9.6) at the recommended concentration was coated in the 96-well polystyrene plates (NUNC MaxiSorp; NUNC AB, Roskilde, Denmark). After overnight incubation at 48C, the excess antibodies were washed off using PBS, 0.1% Tween 20 (Himedia Laboratories, Mumbai, India). The samples were added and incubated for 2 h at 378C room temperature (RT). After washing, secondary antibody (biotinylated antihuman inducible protein-10 mAb) conjugated with peroxidase was incubated for 1 h at RT. Excess antibodies were washed, and tetramethylbenzidine (Sigma-Aldrich Corporation, St Louis, Missouri, USA) was added and incubated for 30 min at RT. The reaction was arrested by the addition of 2 N H 2 SO 4 .
Due to the lack of gold standard for latent TB diagnosis and TB being highly endemic in our setting, we selected those individuals who were HIV seronegative, apparently free of TB symptoms, did not have close family contact of TB, were negative for both QFT-IT and TST and defined them as healthy individuals. To determine the cut-off point for IFNg-inducible protein-10, we measured the IFNg-inducible protein-10 levels in 50 healthy individuals (median 32; age range 21-45 years) and found that IFNg-inducible protein-10 response to TB antigens ranged from 0 to 300 pg/ml. Hence, we chose 300 pg/ml as the cut-off point for IFNg-inducible protein-10 for TB antigens. For mitogen, we chose 200 pg/ml as the cut-off point based on the earlier study results [11] . The individuals with at least 300 pg/ml for TB antigens (TB antigen-nil), irrespective of mitogen response, were considered as positive; individuals with less than 300 pg/ml for TB antigens and at least 200 pg/ml for mitogen were considered as negative; others (<300 pg/ml for TB antigen and <200 pg/ml for mitogen) were considered as indeterminate.
All 50 HIV-TB patients were positive by culture, and the presence of M. tuberculosis was confirmed by Gen-Probe method (Gen-Probe Inc., San Diego, California, USA). The median CD4 cell count was 86 (interquartile range ¼ 38 188) cells/ml, with a range of 11-502 cells/ml (available only for 36 individuals). The IFNg and IFNginducible protein-10 secretion to TB antigen was in the range 0-26 IU/ml (median 1.375 IU/ml) and 0-14 630 pg/ml (median 1309 pg/ml), respectively ( Fig. 1) . Among the 10 QFT-IT indeterminate individuals, five (50%) became positive for IFNg-inducible protein-10 and the other five remained indeterminate. Of the five QFT-IT-negative individuals, three became positive for IFNg-inducible protein-10. One IFNg-inducible protein-10-negative individual was positive for QFT-IT. When indeterminate results were considered as negative, QFT-IT and IFNg-inducible protein-10 yielded 70% and 86% sensitivities, respectively. The sensitivity of IFNg-inducible protein-10 was significantly higher than QFT-IT (P ¼ 0.045). No significant difference in the CD4 cell count was observed between QFT-IT/IFNginducible protein-10-positive and negative individuals. The CD4 cell counts did not significantly differ between QFT-IT-negative/indeterminate and IFNg-inducible protein-10-negative/indeterminate individuals. However, IFNg-inducible protein-10 yielded indeterminate results only when CD4 cell count was less than 50 cells/ml, whereas QFT-IT yielded indeterminate results when CD4 cell count was less than 200 cells/ml.
Our results show that IFNg-inducible protein-10 detected more HIV-TB cases and particularly yielded 50% less indeterminate results when compared with QFT-IT. This is the first study to compare IFNg and IFNg-inducible protein-10 levels in HIV-TB patients recruited from a setting, endemic for both HIV and TB. We speculate the following reasons for higher sensitivity of IFNg-inducible protein-10. First, IFNg-inducible protein-10 is mainly secreted by monocytes/macrophages [15] in contrast to IFNg, which is secreted mainly by CD4 cells and hence less affected by HIV infection and less influenced by low CD4 cell counts when compared with QFT-IT. Second, as IFNg-inducible protein-10 is an amplified signal of IFNg [16, 17] , even small number of IFNg-secreting cells can induce large quantity of IFNginducible protein-10 secretion.
This study was conducted with a small sample size, and CD4 cell counts were available for 36 individuals only, which emphasizes the requirement for further studies on this issue. In addition, the specificity of IFNg-inducible protein-10 also has to be assessed in HIV-positive, TB-negative patients to validate the cut-off point. In conclusion, our preliminary study provides an interesting hypothesis that IFNg-inducible protein-10 may be evaluated as a better alternative marker for LTBI diagnosis in immunocompromised individuals.
